Global Interventional Oncology Market Size, Share & Industry Trends Analysis Report By Cancer Type (Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Prostate Cancer, Bone Metastasis), By Product Type, By End User, By Regional Outlook and Forecast,

Global Interventional Oncology Market Size, Share & Industry Trends Analysis Report By Cancer Type (Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Prostate Cancer, Bone Metastasis), By Product Type, By End User, By Regional Outlook and Forecast, 2022 – 2028

The Global Interventional Oncology Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period.

Interventional oncology (IO) is an emerging subspecialty that emphasizes on using image-guided processes (diagnostics/surgeries) to improve cancer therapy. Along with surgery, medication, and radiation, IO is currently the fourth pillar of modern oncology care. The three key areas of cancer intervention that IO focuses on are diagnosis, therapy, and symptom relief. Improvements in cross-sectional imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) have enabled progress in IO (PET).

Because of the rising number of cancer cases among individuals around the world, the interventional oncology market is expected to rise faster in the coming years. Cancer is one of the most rapidly developing health problems, impacting individuals of different ages. Breast cancer & throat cancer are two of the most common types of cancer in individuals. The need for technologically improved cancer management therapy has expanded in tandem with the rise in the number of cancer patients.

Patients with cancer, both adults and children, have benefited from the innovative interventional oncology therapy line. In the coming years, such advancements are expected to have a positive influence on interventional oncology market growth. IO, along with Medical, Surgical, and Radiation Oncology, has successfully established itself as a significant treatment specialism within multidisciplinary oncologic care. In today's cancer care, IO is currently regarded the fourth pillar. Though surgical removal of tumours is typically thought to be the greatest therapy, it is not always achievable owing to the tumor's size, quantity, or location. IO treatments can be used to reduce a tumour, allowing for surgery or interventional treatment. A few patients may be unable to endure open surgery due to their health.

COVID-19 Impact

Patients have constrained themselves from going to visit hospitals and clinics for diagnosis of medical problems other than coronavirus symptoms owing to the increase incidence of coronaviral transmission. As a result, fewer cancer patients have reported to hospitals for treatment. The market is confronted with production and supply chain problems, such as providing items to end users on time and catering to an inconsistent demand for the sector's products and services. Furthermore, a scarcity of talented lab experts to perform diagnostic tests, restricted operations in most businesses, insufficient financing for research & academic institutes, the temporary closure of main academic institutes, a disrupted supply chain, and obstacles in offering a service owing to lockdowns have all contributed to a decrease in the supply of interventional oncology products to end users. As a result, the pandemic is unlikely to have long-term consequences for the basic growth drivers or end consumers in the economy.

Market Growth Factors

More efficiency and quick recovery offered by interventional oncology

While utilizing medical imaging technologies during vascular therapies, radiologists & technologists have a lot of sight. Professionals can accurately identify and treat diseases throughout the operation, which can take less than an hour in some cases. These procedures are also regarded a more effective usage medical resources than major surgery because they are relatively rapid. Because most outpatient processes, particularly interventional radiology, are less costly than inpatient hospital stays, patients often find interventional radiology to be a more cost-effective therapy.

Shifting preference of people towards minimally invasive procedure

Because of the benefits given by these techniques over traditional treatment processes, the demand for minimally invasive procedures has increased significantly in recent years. Fewer operating complications, shorter hospitalization, reduced pain, smaller & more cosmetic incisions, reduced risk of infection, less post-surgical care, and faster recovery are all benefits of minimally invasive procedures. Sophisticated technology is used in minimally invasive treatments to detect and cure a variety of disorders, including cancer. These treatments are intended to remove malignant tumours and lymph nodes from the body without leaving scars.

Market Restraining Factors

Restricted clinical data to maintain therapeutic efficacy

A medication must have comprehensive safety data from Phase I studies, established effectiveness from Phase II trials, and analysis of clinical results better than current therapies from randomized, controlled Phase III trials before it can be introduced as a standard of care. In addition, performing well-controlled clinical trials in interventional oncology procedures, on the other hand, is challenging owing to a dearth of recognized methodology. Chemoembolization, for example, is the most common treatment for hepatocellular cancer. On the other hand, the clinical evidence for chemoembolization is inadequate, and the clinical advantages generated from current trials are smaller than those derived from other cancer treatment alternatives.

Cancer Type Outlook

Based on Cancer Type, the market is segmented into Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Prostate Cancer, Bone Metastasis, and Others. The liver cancer segment witnessed the maximum revenue share in the interventional oncology market in 2021. Primary liver tumours caused by metastatic cancer can be successfully treated using interventional oncology techniques. Increased research/development efforts using interventional oncology to improve liver cancer therapy, and an increase in the number of instances of liver cancer in the world, are among the factors driving liver sub-growth.

Product Type Outlook

Based on Product Type, the market is segmented into Embolization Devices, Ablation Devices, and Support Devices. The Ablation devices segment acquired a significant revenue share in the interventional oncology market in 2021. Because of the expanding popularity of minimally invasive treatments and the rising frequency of certain soft tissue malignancies, ablation devices provide a minimally invasive option to conventional surgical treatment of liver, kidney, prostate, and lung cancers.

End User Outlook

Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers, and Research & Academic Institutes. Hospitals segment acquired the highest revenue share in the interventional oncology market in 2021. The hospital sub-segment might benefit greatly from advancements in healthcare infrastructure and a boom in the adoption of innovative interventional oncology technologies like embolization and ablation devices in hospitals. Additionally, several patients prefer to undergo cancer treatment from hospitals because numerous innovative treatment facilities are housed under one roof, and patients do not have to worry about their treatment.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia Pacific recorded a significant revenue share in the interventional oncology market in 2021. This is due to a variety of variables, including an increase in cancer cases amongst people and improved healthcare facilities. The key factors propelling the market of the APAC interventional oncology market are government efforts to raise funding, supportive regulations for the manufacture and marketing of innovative interventional oncology products, increasing healthcare expenditure, growing amount of hospitals and clinics in India and China, broadening research base all over China, India, and Japan, and the rising incidences of surgeries.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Teleflex, Inc., Cook Medical, Inc. (Cook Group), Medtronic PLC, Terumo Corporation , Johnson & Johnson (Johnson & Johnson Services, Inc.), Becton, Dickinson and Company, AngioDynamics, Inc., Merit Medical Systems, Inc., and HealthTronics, Inc. (Altaris Capital Partners, LLC)

Scope of the Study

Market Segments covered in the Report:

By Cancer Type

  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Breast Cancer
  • Prostate Cancer
  • Bone Metastasis
  • Others
By Product Type
  • Embolization Devices
  • Ablation Devices
  • Support Devices
By End User
  • Hospitals
  • Ambulatory Surgery Centers
  • Research & Academic Institutes
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Boston Scientific Corporation
  • Teleflex, Inc.
  • Cook Medical, Inc. (Cook Group)
  • Medtronic PLC
  • Terumo Corporation
  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • Becton, Dickinson and Company
  • AngioDynamics, Inc.
  • Merit Medical Systems, Inc.
  • HealthTronics, Inc. (Altaris Capital Partners, LLC)
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Interventional Oncology Market, by Cancer Type
1.4.2 Global Interventional Oncology Market, by Product Type
1.4.3 Global Interventional Oncology Market, by End User
1.4.4 Global Interventional Oncology Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Interventional Oncology Market by Cancer Type
3.1 Global Liver Cancer Market by Region
3.2 Global Lung Cancer Market by Region
3.3 Global Kidney Cancer Market by Region
3.4 Global Breast Cancer Market by Region
3.5 Global Prostate Cancer Market by Region
3.6 Global Bone Metastasis Market by Region
3.7 Global Others Market by Region
Chapter 4. Global Interventional Oncology Market by Product Type
4.1 Global Embolization Devices Market by Region
4.2 Global Ablation Devices Market by Region
4.3 Global Support Devices Market by Region
Chapter 5. Global Interventional Oncology Market by End User
5.1 Global Hospitals Market by Region
5.2 Global Ambulatory Surgery Centers Market by Region
5.3 Global Research & Academic Institutes Market by Region
Chapter 6. Global Interventional Oncology Market by Region
6.1 North America Interventional Oncology Market
6.1.1 North America Interventional Oncology Market by Cancer Type
6.1.1.1 North America Liver Cancer Market by Country
6.1.1.2 North America Lung Cancer Market by Country
6.1.1.3 North America Kidney Cancer Market by Country
6.1.1.4 North America Breast Cancer Market by Country
6.1.1.5 North America Prostate Cancer Market by Country
6.1.1.6 North America Bone Metastasis Market by Country
6.1.1.7 North America Others Market by Country
6.1.2 North America Interventional Oncology Market by Product Type
6.1.2.1 North America Embolization Devices Market by Country
6.1.2.2 North America Ablation Devices Market by Country
6.1.2.3 North America Support Devices Market by Country
6.1.3 North America Interventional Oncology Market by End User
6.1.3.1 North America Hospitals Market by Country
6.1.3.2 North America Ambulatory Surgery Centers Market by Country
6.1.3.3 North America Research & Academic Institutes Market by Country
6.1.4 North America Interventional Oncology Market by Country
6.1.4.1 US Interventional Oncology Market
6.1.4.1.1 US Interventional Oncology Market by Cancer Type
6.1.4.1.2 US Interventional Oncology Market by Product Type
6.1.4.1.3 US Interventional Oncology Market by End User
6.1.4.2 Canada Interventional Oncology Market
6.1.4.2.1 Canada Interventional Oncology Market by Cancer Type
6.1.4.2.2 Canada Interventional Oncology Market by Product Type
6.1.4.2.3 Canada Interventional Oncology Market by End User
6.1.4.3 Mexico Interventional Oncology Market
6.1.4.3.1 Mexico Interventional Oncology Market by Cancer Type
6.1.4.3.2 Mexico Interventional Oncology Market by Product Type
6.1.4.3.3 Mexico Interventional Oncology Market by End User
6.1.4.4 Rest of North America Interventional Oncology Market
6.1.4.4.1 Rest of North America Interventional Oncology Market by Cancer Type
6.1.4.4.2 Rest of North America Interventional Oncology Market by Product Type
6.1.4.4.3 Rest of North America Interventional Oncology Market by End User
6.2 Europe Interventional Oncology Market
6.2.1 Europe Interventional Oncology Market by Cancer Type
6.2.1.1 Europe Liver Cancer Market by Country
6.2.1.2 Europe Lung Cancer Market by Country
6.2.1.3 Europe Kidney Cancer Market by Country
6.2.1.4 Europe Breast Cancer Market by Country
6.2.1.5 Europe Prostate Cancer Market by Country
6.2.1.6 Europe Bone Metastasis Market by Country
6.2.1.7 Europe Others Market by Country
6.2.2 Europe Interventional Oncology Market by Product Type
6.2.2.1 Europe Embolization Devices Market by Country
6.2.2.2 Europe Ablation Devices Market by Country
6.2.2.3 Europe Support Devices Market by Country
6.2.3 Europe Interventional Oncology Market by End User
6.2.3.1 Europe Hospitals Market by Country
6.2.3.2 Europe Ambulatory Surgery Centers Market by Country
6.2.3.3 Europe Research & Academic Institutes Market by Country
6.2.4 Europe Interventional Oncology Market by Country
6.2.4.1 Germany Interventional Oncology Market
6.2.4.1.1 Germany Interventional Oncology Market by Cancer Type
6.2.4.1.2 Germany Interventional Oncology Market by Product Type
6.2.4.1.3 Germany Interventional Oncology Market by End User
6.2.4.2 UK Interventional Oncology Market
6.2.4.2.1 UK Interventional Oncology Market by Cancer Type
6.2.4.2.2 UK Interventional Oncology Market by Product Type
6.2.4.2.3 UK Interventional Oncology Market by End User
6.2.4.3 France Interventional Oncology Market
6.2.4.3.1 France Interventional Oncology Market by Cancer Type
6.2.4.3.2 France Interventional Oncology Market by Product Type
6.2.4.3.3 France Interventional Oncology Market by End User
6.2.4.4 Russia Interventional Oncology Market
6.2.4.4.1 Russia Interventional Oncology Market by Cancer Type
6.2.4.4.2 Russia Interventional Oncology Market by Product Type
6.2.4.4.3 Russia Interventional Oncology Market by End User
6.2.4.5 Spain Interventional Oncology Market
6.2.4.5.1 Spain Interventional Oncology Market by Cancer Type
6.2.4.5.2 Spain Interventional Oncology Market by Product Type
6.2.4.5.3 Spain Interventional Oncology Market by End User
6.2.4.6 Italy Interventional Oncology Market
6.2.4.6.1 Italy Interventional Oncology Market by Cancer Type
6.2.4.6.2 Italy Interventional Oncology Market by Product Type
6.2.4.6.3 Italy Interventional Oncology Market by End User
6.2.4.7 Rest of Europe Interventional Oncology Market
6.2.4.7.1 Rest of Europe Interventional Oncology Market by Cancer Type
6.2.4.7.2 Rest of Europe Interventional Oncology Market by Product Type
6.2.4.7.3 Rest of Europe Interventional Oncology Market by End User
6.3 Asia Pacific Interventional Oncology Market
6.3.1 Asia Pacific Interventional Oncology Market by Cancer Type
6.3.1.1 Asia Pacific Liver Cancer Market by Country
6.3.1.2 Asia Pacific Lung Cancer Market by Country
6.3.1.3 Asia Pacific Kidney Cancer Market by Country
6.3.1.4 Asia Pacific Breast Cancer Market by Country
6.3.1.5 Asia Pacific Prostate Cancer Market by Country
6.3.1.6 Asia Pacific Bone Metastasis Market by Country
6.3.1.7 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Interventional Oncology Market by Product Type
6.3.2.1 Asia Pacific Embolization Devices Market by Country
6.3.2.2 Asia Pacific Ablation Devices Market by Country
6.3.2.3 Asia Pacific Support Devices Market by Country
6.3.3 Asia Pacific Interventional Oncology Market by End User
6.3.3.1 Asia Pacific Hospitals Market by Country
6.3.3.2 Asia Pacific Ambulatory Surgery Centers Market by Country
6.3.3.3 Asia Pacific Research & Academic Institutes Market by Country
6.3.4 Asia Pacific Interventional Oncology Market by Country
6.3.4.1 China Interventional Oncology Market
6.3.4.1.1 China Interventional Oncology Market by Cancer Type
6.3.4.1.2 China Interventional Oncology Market by Product Type
6.3.4.1.3 China Interventional Oncology Market by End User
6.3.4.2 Japan Interventional Oncology Market
6.3.4.2.1 Japan Interventional Oncology Market by Cancer Type
6.3.4.2.2 Japan Interventional Oncology Market by Product Type
6.3.4.2.3 Japan Interventional Oncology Market by End User
6.3.4.3 India Interventional Oncology Market
6.3.4.3.1 India Interventional Oncology Market by Cancer Type
6.3.4.3.2 India Interventional Oncology Market by Product Type
6.3.4.3.3 India Interventional Oncology Market by End User
6.3.4.4 South Korea Interventional Oncology Market
6.3.4.4.1 South Korea Interventional Oncology Market by Cancer Type
6.3.4.4.2 South Korea Interventional Oncology Market by Product Type
6.3.4.4.3 South Korea Interventional Oncology Market by End User
6.3.4.5 Singapore Interventional Oncology Market
6.3.4.5.1 Singapore Interventional Oncology Market by Cancer Type
6.3.4.5.2 Singapore Interventional Oncology Market by Product Type
6.3.4.5.3 Singapore Interventional Oncology Market by End User
6.3.4.6 Malaysia Interventional Oncology Market
6.3.4.6.1 Malaysia Interventional Oncology Market by Cancer Type
6.3.4.6.2 Malaysia Interventional Oncology Market by Product Type
6.3.4.6.3 Malaysia Interventional Oncology Market by End User
6.3.4.7 Rest of Asia Pacific Interventional Oncology Market
6.3.4.7.1 Rest of Asia Pacific Interventional Oncology Market by Cancer Type
6.3.4.7.2 Rest of Asia Pacific Interventional Oncology Market by Product Type
6.3.4.7.3 Rest of Asia Pacific Interventional Oncology Market by End User
6.4 LAMEA Interventional Oncology Market
6.4.1 LAMEA Interventional Oncology Market by Cancer Type
6.4.1.1 LAMEA Liver Cancer Market by Country
6.4.1.2 LAMEA Lung Cancer Market by Country
6.4.1.3 LAMEA Kidney Cancer Market by Country
6.4.1.4 LAMEA Breast Cancer Market by Country
6.4.1.5 LAMEA Prostate Cancer Market by Country
6.4.1.6 LAMEA Bone Metastasis Market by Country
6.4.1.7 LAMEA Others Market by Country
6.4.2 LAMEA Interventional Oncology Market by Product Type
6.4.2.1 LAMEA Embolization Devices Market by Country
6.4.2.2 LAMEA Ablation Devices Market by Country
6.4.2.3 LAMEA Support Devices Market by Country
6.4.3 LAMEA Interventional Oncology Market by End User
6.4.3.1 LAMEA Hospitals Market by Country
6.4.3.2 LAMEA Ambulatory Surgery Centers Market by Country
6.4.3.3 LAMEA Research & Academic Institutes Market by Country
6.4.4 LAMEA Interventional Oncology Market by Country
6.4.4.1 Brazil Interventional Oncology Market
6.4.4.1.1 Brazil Interventional Oncology Market by Cancer Type
6.4.4.1.2 Brazil Interventional Oncology Market by Product Type
6.4.4.1.3 Brazil Interventional Oncology Market by End User
6.4.4.2 Argentina Interventional Oncology Market
6.4.4.2.1 Argentina Interventional Oncology Market by Cancer Type
6.4.4.2.2 Argentina Interventional Oncology Market by Product Type
6.4.4.2.3 Argentina Interventional Oncology Market by End User
6.4.4.3 UAE Interventional Oncology Market
6.4.4.3.1 UAE Interventional Oncology Market by Cancer Type
6.4.4.3.2 UAE Interventional Oncology Market by Product Type
6.4.4.3.3 UAE Interventional Oncology Market by End User
6.4.4.4 Saudi Arabia Interventional Oncology Market
6.4.4.4.1 Saudi Arabia Interventional Oncology Market by Cancer Type
6.4.4.4.2 Saudi Arabia Interventional Oncology Market by Product Type
6.4.4.4.3 Saudi Arabia Interventional Oncology Market by End User
6.4.4.5 South Africa Interventional Oncology Market
6.4.4.5.1 South Africa Interventional Oncology Market by Cancer Type
6.4.4.5.2 South Africa Interventional Oncology Market by Product Type
6.4.4.5.3 South Africa Interventional Oncology Market by End User
6.4.4.6 Nigeria Interventional Oncology Market
6.4.4.6.1 Nigeria Interventional Oncology Market by Cancer Type
6.4.4.6.2 Nigeria Interventional Oncology Market by Product Type
6.4.4.6.3 Nigeria Interventional Oncology Market by End User
6.4.4.7 Rest of LAMEA Interventional Oncology Market
6.4.4.7.1 Rest of LAMEA Interventional Oncology Market by Cancer Type
6.4.4.7.2 Rest of LAMEA Interventional Oncology Market by Product Type
6.4.4.7.3 Rest of LAMEA Interventional Oncology Market by End User
Chapter 7. Company Profiles
7.1 Boston Scientific Corporation
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Teleflex, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Cook Medical, Inc. (Cook Group)
7.3.1 Company Overview
7.4 Medtronic PLC
7.4.1 Company overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent Strategies and Developments
7.4.5.1 Product Launches and Product Expansions:
7.4.6 SWOT Analysis
7.5 Terumo Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Regional Analysis
7.5.5 Recent Strategies and Developments
7.5.5.1 Partnerships, Collaborations and Agreements:
7.5.5.2 Acquisitions and Mergers:
7.6 Johnson & Johnson (Johnson & Johnson Services, Inc.)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental &Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 SWOT Analysis
7.7 Becton, Dickinson and Company
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 AngioDynamics, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Merit Medical Systems, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.10. HealthTronics, Inc. (Altaris Capital Partners, LLC)
7.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings